Stoke completes enrollment of 162 patients in Phase 3 EMPEROR study of zorevunersen for Dravet syndrome

Stoke Therapeutics, Inc.

Completed enrollment of 162 patients in Phase 3 EMPEROR study of zorevunersen for Dravet syndrome.
Plans to initiate rolling NDA submission to FDA in Q1 2027; data readout anticipated in Q3 2027.
Approximately 50 of 162 patients have passed 28-week primary endpoint measurement; no discontinuations.
Additional cohort of ~30 patients enrolling in Europe; last patient expected in August.
Potential FDA approval and U.S. launch by early 2028.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.